Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pylera-based quadruple therapy versus omeprazole + amoxicillin + clarithromycin for Helicobacter pylori eradication
NL-OMON32065Phase 3Active, not recruiting
- Sponsor
- Axcan Pharma Inc.
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride, omeprazole, amoxicillin and clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Axcan Pharma Inc. Started Mar 2009; status: active, not recruiting.
02
Drugs
bismuth subcitrate potassium + metronidazole + tetracycline hydrochlorideomeprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NL-OMON32065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32065.